United Therapeutics gets disappointing news on cancer therapy

United Therapeutics Corp. ’s (NASDAQ: UTHR) trial of one of its cancer therapies in small cell lung cancer did not achieve its goals, the company announced Monday. The Silver Spring company conducted a trial, called a DISTINCT study, of Unituxin in patients with some forms of small cell lung cancer, but said Monday that the therapy did not extend the overall survival of those patients.  Unituxin, or dinutuximab, first received approval from the Food and Drug Administration in March 2015 to treat…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news